{"success":true,"data":{"pressRelease":{"id":"32397","rtpr_id":"nGNX7yc8gz","ticker":"WGS","exchange":"NASDAQ","all_tickers":["WGS"],"title":"INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of GeneDx Holdings Corp. - WGS","author":"Globe Newswire","published_at":"2026-05-12T20:25:06.042Z","article_body":"NEW YORK, May 12, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating\nclaims on behalf of investors of GeneDx Holdings Corp. (“GeneDx” or the\n“Company”) (NASDAQ: WGS).  Such investors are advised to contact Danielle\nPeyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.\n\nThe investigation concerns whether GeneDx and certain of its officers and/or\ndirectors have engaged in securities fraud or other unlawful business\npractices. \n\n[Click here for information about joining the class action]\n(https://www.globenewswire.com/Tracker?data=d8KsF_DF8ZnUJdHl607ThgfH2IH7w6TbZnv6I7n48Rx2KRncUKKA2ZARSQCO8B9wUBJxEWK3a68pVwv8cTMSPOq3sZzUoPfijtUldYyJtE6XuclUvi8gzXYsMhZn7qcwvTGUOTUib-k6e8RUlxFrIFWuHJPObrzrYBJu877Pu_Jh5-j6f5eNu9APZgoMzVaFZ90S3wiaPLTbNVLmQUYhmgb3yd8KlPiiy2ia517Gpv4=)\n\nOn May 4, 2026, GeneDx reported its first quarter 2026 financial results and\nupdated its full-year outlook.  Among other things, the Company disclosed\ntotal revenue of $102.3 million, exome and genome revenue of $90.6 million,\nand exome and genome test volume growth of 34% year-over-year.  Despite this\nstrong volume growth, GeneDx disclosed that exome and genome revenue increased\nonly 27% year-over-year.  The Company also reduced its full-year 2026 revenue\nguidance to $475 million to $490 million, compared to prior guidance of $540\nmillion to $555 million, and reduced its expected growth in exome and genome\nrevenue to at least 20%, compared to prior guidance of 33% to 35%.  During\nthe associated earnings call, GeneDx further disclosed that total revenue was\napproximately $12 million below expectations, including approximately $5.5\nmillion due to a lower-than-expected blended average reimbursement rate for\nexome and genome testing, and approximately $6.5 million due to\nsofter-than-expected performance from non-core business lines. \n\nOn this news, GeneDx’s stock price fell $33.42 per share, or 49.20%, to\nclose at $34.51 per share on May 5, 2026.\n\nPomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris,\nand Tel Aviv, is acknowledged as one of the premier firms in the areas of\ncorporate, securities, and antitrust class litigation. Founded by the late\nAbraham L. Pomerantz, known as the dean of the class action bar, Pomerantz\npioneered the field of securities class actions. Today, more than 85 years\nlater, Pomerantz continues in the tradition he established, fighting for the\nrights of the victims of securities fraud, breaches of fiduciary duty, and\ncorporate misconduct. The Firm has recovered numerous multimillion-dollar\ndamages awards on behalf of class members. See www.pomlaw.com.\n\nAttorney advertising. Prior results do not guarantee similar outcomes.  \n\nCONTACT:\nDanielle Peyton\nPomerantz LLP\ndpeyton@pomlaw.com\n646-581-9980 ext. 7980\n\n\n\nGlobeNewswire, Inc. 2026","article_body_html":"","raw_payload":{"data":{"id":"nGNX7yc8gz","title":"INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of GeneDx Holdings Corp. - WGS","author":"Globe Newswire","ticker":"WGS","created":"2026-05-12T20:25:06.042Z","tickers":["WGS"],"exchange":"NASDAQ","article_body":"NEW YORK, May 12, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating\nclaims on behalf of investors of GeneDx Holdings Corp. (“GeneDx” or the\n“Company”) (NASDAQ: WGS).  Such investors are advised to contact Danielle\nPeyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.\n\nThe investigation concerns whether GeneDx and certain of its officers and/or\ndirectors have engaged in securities fraud or other unlawful business\npractices. \n\n[Click here for information about joining the class action]\n(https://www.globenewswire.com/Tracker?data=d8KsF_DF8ZnUJdHl607ThgfH2IH7w6TbZnv6I7n48Rx2KRncUKKA2ZARSQCO8B9wUBJxEWK3a68pVwv8cTMSPOq3sZzUoPfijtUldYyJtE6XuclUvi8gzXYsMhZn7qcwvTGUOTUib-k6e8RUlxFrIFWuHJPObrzrYBJu877Pu_Jh5-j6f5eNu9APZgoMzVaFZ90S3wiaPLTbNVLmQUYhmgb3yd8KlPiiy2ia517Gpv4=)\n\nOn May 4, 2026, GeneDx reported its first quarter 2026 financial results and\nupdated its full-year outlook.  Among other things, the Company disclosed\ntotal revenue of $102.3 million, exome and genome revenue of $90.6 million,\nand exome and genome test volume growth of 34% year-over-year.  Despite this\nstrong volume growth, GeneDx disclosed that exome and genome revenue increased\nonly 27% year-over-year.  The Company also reduced its full-year 2026 revenue\nguidance to $475 million to $490 million, compared to prior guidance of $540\nmillion to $555 million, and reduced its expected growth in exome and genome\nrevenue to at least 20%, compared to prior guidance of 33% to 35%.  During\nthe associated earnings call, GeneDx further disclosed that total revenue was\napproximately $12 million below expectations, including approximately $5.5\nmillion due to a lower-than-expected blended average reimbursement rate for\nexome and genome testing, and approximately $6.5 million due to\nsofter-than-expected performance from non-core business lines. \n\nOn this news, GeneDx’s stock price fell $33.42 per share, or 49.20%, to\nclose at $34.51 per share on May 5, 2026.\n\nPomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris,\nand Tel Aviv, is acknowledged as one of the premier firms in the areas of\ncorporate, securities, and antitrust class litigation. Founded by the late\nAbraham L. Pomerantz, known as the dean of the class action bar, Pomerantz\npioneered the field of securities class actions. Today, more than 85 years\nlater, Pomerantz continues in the tradition he established, fighting for the\nrights of the victims of securities fraud, breaches of fiduciary duty, and\ncorporate misconduct. The Firm has recovered numerous multimillion-dollar\ndamages awards on behalf of class members. See www.pomlaw.com.\n\nAttorney advertising. Prior results do not guarantee similar outcomes.  \n\nCONTACT:\nDanielle Peyton\nPomerantz LLP\ndpeyton@pomlaw.com\n646-581-9980 ext. 7980\n\n\n\nGlobeNewswire, Inc. 2026"},"type":"article","timestamp":"2026-05-12T20:25:06.080994665Z","server_sent_at_ms":1778617506080},"received_at":"2026-05-12T20:25:06.146Z","source_url":null},"analysis":{"id":"23334","press_release_id":"32397","analysis_json":{"redFlags":[],"eventType":"legal_litigation","narrative":"Pomerantz Law Firm is investigating claims on behalf of investors of GeneDx Holdings Corp.\n\nThe investigation focuses on potential securities fraud or other unlawful business practices by the company and its officers or directors.\n\nInvestors are advised to contact Danielle Peyton at Pomerantz LLP for more information.","sentiment":"neutral","agentHooks":{"shouldPost":false,"suggestedAngle":"Plaintiff-firm solicitation -- suppress."},"keyFigures":{},"quotedText":"","namedEntities":{"people":[{"name":"Danielle Peyton","role":"Contact at Pomerantz LLP"}],"products":[],"companies":[{"name":"GeneDx Holdings Corp.","ticker":"WGS","relationship":"target"},{"name":"Pomerantz LLP","relationship":"plaintiff law firm"}],"dollarAmounts":[]},"materialImpact":{"score":1,"reasoning":"Plaintiff law-firm shareholder solicitation issued by Pomerantz Law Firm. No new disclosure from the issuer; no certified class, no settlement. Boilerplate lead-plaintiff-deadline reminder."},"tickerRelevance":{"others":[],"primary":"WGS"},"globalImportance":15,"audienceRelevance":10,"eventTypeSecondary":[],"importanceComponents":{"tickerTier":"small-cap","eventGravity":"law-firm-solicitation","issuerAuthored":false}},"event_type":"legal_litigation","event_type_secondary":null,"sentiment":"neutral","material_impact_score":1,"narrative":"Pomerantz Law Firm is investigating claims on behalf of investors of GeneDx Holdings Corp.\n\nThe investigation focuses on potential securities fraud or other unlawful business practices by the company and its officers or directors.\n\nInvestors are advised to contact Danielle Peyton at Pomerantz LLP for more information.","key_figures":{},"named_entities":{"people":[{"name":"Danielle Peyton","role":"Contact at Pomerantz LLP"}],"products":[],"companies":[{"name":"GeneDx Holdings Corp.","ticker":"WGS","relationship":"target"},{"name":"Pomerantz LLP","relationship":"plaintiff law firm"}],"dollarAmounts":[]},"model_name":"Qwen/Qwen2.5-72B-Instruct-AWQ","prompt_hash":"sha256:a68c0d5c02b24190","schema_hash":"sha256:4b22e0a142e5d4b1","created_at":"2026-05-12T20:26:08.387Z","global_importance":15,"audience_relevance":10,"importance_components":{"tickerTier":"small-cap","eventGravity":"law-firm-solicitation","issuerAuthored":false}},"durationMs":62225,"modelName":"george-droid-qwen-72b"}}